Highlights NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Delayed NSE India S.E. Other stock markets 01:53:28 2024-04-29 am EDT			5-day change	1st Jan Change
1,010 ^INR	-1.71%		+0.52%	+24.59%

Apr. 09	Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	MT
Mar. 27	NATCO Pharma Limited Announces Board Appointments	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Natco Pharma Gets US FDA Warning Letter after Inspection of Kothur, India Unit	Apr. 09	MT
NATCO Pharma Limited Revises Earnings Guidance for the Fiscal Year 2024	Feb. 15	CI
Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024	Feb. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 14	CI
Natco Pharma's Consolidated Profit Soars in Fiscal Q2, Declares Second Interim Dividend	Nov. 14	MT
NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023	Nov. 14	CI
NATCO Pharma Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
US FDA Clears Natco Pharma's Pharmacovigilance Department in Hyderabad, India	Nov. 02	MT
Natco Pharma, Three Others Face Antitrust Violation Raps in US; Natco Pharma Shares Drop 3%	23-09-08	MT
Bristol Myers accused of illegal tactics to keep Pomalyst monopoly in lawsuit	23-09-06	RE
Natco Pharma to Form UK Arm	23-08-09	MT
NATCO Pharma Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-09	CI
NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24	23-08-09	CI
Natco Pharma Limited Receives Final Approval for Tipiracil Hydrochloride and Trifluridine (Generic for LonsurfÂ®) for the US Market	23-06-15	CI
Natco Pharma Gets US FDA's Establishment Inspection Report After Vizag Unit Inspection	23-06-15	MT
NATCO Pharma Seeks Acquisitions	23-06-06	CI
NATCO Pharma Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
NATCO Pharma Limited agreed to acquire Zista Pharma Limited for $3 million.	23-05-28	CI
Tranche Update on NATCO Pharma Limited's Equity Buyback Plan announced on March 8, 2023.	23-05-12	CI
Tranche Update on NATCO Pharma Limited's Equity Buyback Plan announced on March 8, 2023.	23-05-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NATCO Pharma Limited

Equities

NATCOPHARM

INE987B01026

Highlights

Filters